Santaris, miRagen extend partnership on microRNA therapeutic research
The agreement allows miRagen to gain a non-exclusive license to the miRNA therapeutics field and global rights to develop and commercialize LNA drugs targeting six additional microRNAs. Santaris
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.